The EmmY (Epidemiology of Multiple MYeloma) cohort is a national real world evidence initiative conducted under the aegis of the Intergroupe Francophone du Myélome (IFM), the leading French academic network specializing in multiple myeloma. The project is implemented jointly by IFM, Kappa Santé, and a consortium of pharmaceutical companies.
The study was proposed to all IFM member centers, with 73 expert hematology centers selected to participate. Its objective is to generate high-quality, long-term real-world data on the therapeutic management of multiple myeloma in France.
Multiple myeloma is a complex and rapidly evolving disease area, requiring longitudinal, high-quality real-world data to understand changes in treatment patterns and patient outcomes over time. To succeed, the project required strong scientific governance, operational rigor, and a partner with deep expertise in real-world evidence generation.
Kappa Santé played a central role in the design, implementation, and operational management of the EmmY cohort.
Key elements of the approach included:
This structured yet flexible model allowed the study to evolve alongside changes in clinical practice while maintaining data consistency. The EmmY cohort has become one of the most comprehensive sources of real-world data on multiple myeloma in France.
The EmmY cohort demonstrates APICES and Kappa Santé’s ability to deliver large-scale, long-term RWE programs with scientific credibility and operational excellence.
